Company profile: Aequus Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of ophthalmology and transplant treatments and devices, offering Tacrolimus IR for organ rejection prophylaxis and refractory rejection; Vistitan and Zimed PF (bimatoprost 0.03%) to reduce intraocular pressure; Evolve preservative-free lubricating eye drops; the Zepto Capsulotomy System for cataract surgery; and REV-0100, a potential therapy for Stargardt disease.
Products and services
- Zimed PF: A preservative-free bimatoprost 0.03% eye drop that lowers intraocular pressure in ocular hypertension or glaucoma, tailored for patients sensitive to preservatives or with ocular surface disease
- Tacrolimus IR: A generic immunosuppressant for prophylaxis of organ rejection in allogeneic liver, kidney, or heart transplants, and treatment of refractory rejection in allogeneic liver or kidney recipients
- Vistitan: An ophthalmic solution containing bimatoprost 0.03% that reduces elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Aequus Pharmaceuticals
Neuron Bio
HQ: Spain
Website
- Description: Provider of innovative biosolutions: AlzTEST blood biomarker diagnostic for Alzheimer’s; Omega-3 DHA microalgae oil for functional foods and nutraceuticals; MicroBiOil platform for microbial oils and oleochemicals; Microbiotools by Neol for bioprocess development; custom R&D in biomedicine, toxicology and agro-food; and a drug discovery platform for neurodegenerative diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Neuron Bio company profile →
Diagnamed
HQ: Canada
Website
- Description: Provider of digital health AI platforms and tools to improve brain health, including BRAIN AGE AI for estimating brain age and assessing cognitive decline using EEG and machine learning; CERVAI Brain Health AI for assessments and research with generative AI; Dr. GenAI, a healthcare chatbot; PalGPT.ai for brain health applications; and FormGPT.io for healthcare applications.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Diagnamed company profile →
Anavex Life Sciences
HQ: United States
Website
- Description: Provider of biopharmaceutical drug candidates for cancer and neurological diseases, including ANAVEX 2-73 (blarcamesine), an orally available small-molecule activator of the sigma-1 receptor (SIGMAR1) for Alzheimer's, Parkinson's, and Rett syndrome; ANAVEX 3-71 targeting sigma-1 and M1 muscarinic receptors for schizophrenia, Alzheimer's, and frontotemporal dementia; and the SIGMACEPTOR Discovery Platform for CNS disorders.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Anavex Life Sciences company profile →
Avanir Pharmaceuticals
HQ: United States
Website
- Description: Provider of biopharmaceutical medicines for central nervous system disorders, focused on high unmet medical need. Offers Nuedexta, a medication used to treat pseudobulbar affect (PBA), characterized by sudden, uncontrollable episodes of crying or laughing. Extensively invests in its pipeline and is dedicated to advancing medicines that can substantially improve patients' lives.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Avanir Pharmaceuticals company profile →
Pharnext
HQ: France
Website
- Description: Provider of clinical-stage biopharmaceutical therapeutics for severe neurodegenerative diseases, developing PXT3003 for Charcot-Marie-Tooth disease type 1A using its Pleotherapy approach (Phase III), and PXT864, a fixed-dose combination of baclofen and acamprosate progressing to Phase 2a in ALS; also sponsors CMT&Me, an app-based international study of CMT patient lifestyles.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Pharnext company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Aequus Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Aequus Pharmaceuticals
2.2 - Growth funds investing in similar companies to Aequus Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Aequus Pharmaceuticals
4.2 - Public trading comparable groups for Aequus Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →